Discover Insmed's innovative therapies targeting rare diseases, with approvals like Brinsupri boosting potential.

Insmed (INSM) saw a significant price move of 87% over the past quarter, driven by pivotal product developments and regulatory milestones. The FDA's approval of BRINSUPRI as the first oral treatment ...

The FDA has approved oral brensocatib (Brinsupri) for adults and children 12+ with non-cystic fibrosis bronchiectasis. As a ...

The FDA has approved Insmed’s Brinsupri™ (brensocatib 10 mg and 25 mg tablets) as the first drug authorized to treat ...

Amber Specialty Pharmacy, a pioneer in specialty pharmacy for more than 25 years, today announced it is now dispensing ...

JPMorgan raised the firm’s price target on Insmed (INSM) to $135 from $111 and keeps an Overweight rating on the shares. The firm sees Brinsupri ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

William Blair initiated coverage of Insmed (INSM) with an Outperform rating. The firm believes that clinical and commercial execution with ...

Last week, PureTech Health spun out a new company, Celea Therapeutics, which will develop its pulmonary fibrosis candidate ...

A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol ...